Back to search

Article

The N6-methyladenosine-modified Pseudogene HSPA7 Correlates with the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma

2020-12-22

Abstract excerpt

<h4>Background: </h4> Glioblastoma (GBM), one of the most aggressive cancers in brain tumor type, have no effective and sufficient therapies. Identifying robust biomarkers of immune checkpoint blockade (ICB) therapy, a promising treatment option for GBM patients, are urgently warranted. <h4>Methods: </h4>: We comprehensively evaluated the m 6 A modification patterns of lncRNAs via m 6 A-sequencing (m 6 A-seq) data...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
64b7286c-64eb-58be-b08e-dd8cd0611bd6
DOI
10.21203/rs.3.rs-130869/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The N6-methyladenosine-modified Pseudogene HSPA7 Correlates with the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in GlioblastomaDOI 10.21203/rs.3.rs-130869/v1
Select a neighboring publication to make it the new centre.